Pill Burden in Hypertensive Patients Treated with Single-Pill Combination Therapy — An Observational Study by unknown
Adv Ther (2013)  30(4):406–19.
DOI 10.1007/s12325-013-0018-3
ORIGINAL RESEARCH
Pill Burden in Hypertensive Patients Treated with  
Single-Pill Combination Therapy – An Observational Study
Andreas Hagendorff · Siegfried Freytag · Alfons Müller · Sven Klebs 
To view enhanced content go to www.advancesintherapy.com
Received: February 4, 2013 / Published online: March 25, 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Hypertension is a condition which 
in many cases is treated with more than one 
drug. Additionally, patients with hypertension 
often suffer from other concomitant diseases, 
such as diabetes mellitus or dyslipidemia, which 
adds to the number of pills that patients need 
to take (pill burden). The aim of this study was 
to investigate the impact of this pill burden on 
patients with hypertension in clinical practice 
in Germany.
Methods: This prospective, open-label, 
observational study enrolled adult patients for 
whom their physician considered treatment 
with a single-pill combination of amlodipine, 
valsartan, and hydrochlorothiazide as indicated. 
At the start of the observation period, physicians 
and patients filled in a respective questionnaire.
Results: The questionnaires of 7,101 patients 
and 905 physicians were analyzed. The survey 
among the patients showed that the majority 
of patients felt burdened by the high number 
of pills to be taken. This was also seen as 
a potential reason for medication errors. 
Approximately half of the patients would be 
willing to make an out-of-pocket payment 
for reducing the number of pills to half. The 
results of the physician questionnaire indicate 
that the physicians were well aware of the set 
of problems that is generally associated with 
the high pill burden and that there is a clear 
willingness to use combination products in 
order to reduce the pill burden.
Conclusion: A high number of pills is considered 
a burden by the patients. This burden increases 
with the number of pills taken per day.
Keywords: Amlodipine; Cardiology; Combination 
therapy; Germany; Hydrochlorothiazide; 
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Diabetes mellitus, and disorders of the lipid 
metabolism and the metabolic syndrome are 
major concomitant diseases found in patients 
with hypertension [14]. Because of these 
comorbidities, the use of multiple drugs is 
common and is recommended by international 
guidelines [14, 15].
The aim of the present noninterventional 
study SIMPLIFY (Nicht-interventionelle 
Studie mit Exforge HCT® zum Einfluss der 
Polypharmakotherapie auf Hypertoniker; a 
noninterventional study with Exforge HCT®
concerning the influence of polypharmacy on 
patients with hypertension) was to investigate 
how both patients with hypertension and 
their treating physicians deal with the high 
numbers of pills, and what kind of challenges 
they are facing. 
Additionally, the SIMPLIFY study aimed 
to estimate the effectiveness of a single-pill 
triple therapy with amlodipine, valsartan, 
and hydrochlorothiazide (A+V+H) in routine 




The SIMPLIFY study was conducted as a 
prospective, open-label, observational, 
multicenter study between November 2009 
and November 2010 in practices of 1,269 
general practitioners and internists in Germany. 
The study was notified in accordance with 
§ 67 (6) German Drugs Law (AMG) and 
conducted according to the applicable regulatory 
requirements and recommendations. All 
procedures followed were in accordance with the 
ethical standards of the responsible committee 
on human experimentation (institutional and 
national) and with the Helsinki Declaration 
Hypertension; Observational study; Pill burden; 
Triple therapy; Valsartan
INTRODUCTION
Hypertension is one of the main risk factors 
for cardiovascular diseases [1]. Its prevalence 
has increased worldwide and is predicted to 
further increase [1, 2]. This situation is further 
complicated by the fact that a considerable 
percentage of patients with hypertension have not 
been diagnosed as such and are, thus, not under 
treatment. A large portion of treated patients do 
not reach target blood pressure [3]. The results 
of a meta-analysis of 147 randomized studies 
underline the importance of blood pressure-
lowering treatments. For each reduction by 
10 mmHg in systolic blood pressure or by 
5 mmHg in diastolic blood pressure, a 22% 
reduction in events due to coronary heart disease 
and a 41% reduction in stroke was observed [4].
Results of controlled studies show that 
blood pressure adjustments to values below 
140/90 mmHg are possible, even if two or more 
antihypertensive drugs are needed [5–9]. Another 
meta-analysis, using 63 studies (including 6 studies 
in hypertension) showed that patients with high 
adherence to their treatment schedule have a 
much higher chance to reach target blood pressure 
than patients with low adherence to treatment 
schedule (odds ratio [OR] 3.44; 95% confidence 
interval [CI] 1.60, 7.37). [10]. This confirms the 
important role of compliance/adherence in 
reaching the target blood pressure and in avoiding 
cardiovascular events [11].
One factor that has a major influence on 
treatment compliance is the so-called pill burden, 
i.e., the number of pills the patient needs to take per 
day. Studies have indicated that higher pill burden 
led to decreased treatment compliance [12, 13]. 
In many cases, hypertension is not the only 
condition that a given patient suffers from. 
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questionnaire concerning the influence of the 
number of pills (nine items) and physicians 
filled in a questionnaire concerning the impact 
of the number of pills in daily practice (six 
items). Details on the questions are given in 
Table 1. At the end of the study, effectiveness 
and tolerability was assessed by the physician. 
Adverse events (AEs) were reported during the 
whole study according to local regulations.
It was the aim of the SIMPLIFY study to 
evaluate the two questionnaires collected at 
baseline, and the effectiveness and safety/
tolerability of A+V+H. Additional parameters 
documented in the study included demographic 
and diagnostic data, cardiovascular risk factors, 
prior and concomitant diseases relevant to 
the indication, information on potential 
antihypertensive pretreatment, and total 
number of pills (overall and for treatment 
of hypertension). Vital signs were assessed 
according to clinical practice and documented 
as well as A+V+H dose, and antihypertensive 
concomitant medication at the start and the end 
of the observation period, and the optional visit 
in between. 
The data in all documentation forms were 
examined for their plausibility by the data 
management department. Additionally, for a 
defined percentage (2%, in line with common 
practice in Germany [16]) of randomly chosen 
study centers, the documentation forms were 
compared with the source documents during 
on-site monitoring.
Data Analysis
According to the predefined statistical analysis plan, 
the statistical evaluation was carried out using basic 
descriptive statistical methods and was interpreted 
in an explorative way. In the publication, the 
results of the overall population is shown as 
well as analyses based on the number of pills. 
of 1975, as revised in 2000, and as far as 
applicable for observational, noninterventional 
studies. Informed consent was obtained 
from all patients for being included in the 
study. The participating physicians received a 
compensation for the documentation of each 
patient in accordance with the official scale of 
physicians’ fees (Gebührenordnung für Ärzte, 
GOÄ). The study was approved by the respective 
Ethics Committee.
Patients were treated according to medical 
and therapeutic needs. The procedures and 
decisions of the physicians were not influenced 
and the temporal frequency of examinations was 
to be according to practice routine. Additional 
examinations exceeding the usual scope were 
not required.
Study Population
Patients of either gender suffering from 
essential hypertension for whom treatment 
with A+V+H was indicated according to the 
physician’s opinion were included into this 
noninterventional study. There were no 
additional inclusion criteria (e.g., severity 
of hypertension). There were no predefined 
exc lus ion  c r i t e r i a ,  except  fo r  the 
contraindications mentioned in the respective 
summary of product characteristics (SmPC). 
All dosages of A+V+H available in the German 
market could be used. 
Study Conduct and Assessments
The observational period per patient was 
approximately 3–4 months. An examination 
was to be documented by the physician at the 
start and the end of the observation period. 
Optionally, physicians could document an 
additional visit in between. At the start of 
the observational period, patients filled in a 
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Table 1  Patient questionnaire (a) and physician questionnaire (b) (continued on next page)
(a)
Patient questionnaire
No. Questions/items Potential answers




Agree Disagree Strongly 
disagree
2) e number of pills I have to take has an 
inuence on how sick I feel.
Strongly 
agree
Agree Disagree Strongly 
disagree
3) Do you need help to prepare the intake of 
tablets for the day/week at home?
Yes No
4) In case you prepare the intake of your drugs 
yourself, what is the mean amount of time 
needed on average per day for this task? 
(Min)
5) a. Are pill color and shape a signicant help for 
orientation during drug intake?
Yes No
b. If yes to the previous question: e correct use 
of drugs is harder for me when their appearance 
changes, e.g., caused by a change in compound. 
Strongly 
agree
Agree Disagree Strongly 
disagree
6) I am worried that I erroneously forget pills or 
take the wrong pills/the wrong dose.
Strongly 
agree
Agree Disagree Strongly 
disagree
7) a. Does it happen that you are uncertain about 
whether you have already taken your pills or 
not?
Yes No
b. If yes to the previous question: How oen does 
this happen?
Oen Sometimes Rarely Very rarely
8) If it was theoretically possible to change your 
pill count while keeping the quality of your 
medical care unchanged – what maximal 
number of pills per day would you consider 
your personal acceptable limit?
(Number) No limit
9) a. If it was theoretically possible to halve your pill 
count while keeping the quality of your medical 
care unchanged – would you be prepared to 
make an additional out-of-pocket payment for 
this?
Yes No
b. If yes to the previous question: What amount 
would you be willing to pay additionally?
Up to 5€ 
per month
Up to 10€ 
per month
Up to 20€ 
per month
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For some questions additional subgroups (age 
and concomitant disease) are presented. The 
statistical evaluation was carried out using SAS®




Patients were enrolled in 905 practices 
in Germany. For 7,181 patients, filled-in 
questionnaires were available. Of these, 7,101 
patients were analyzed. 
Slightly more than half of the patients were 
male and >60 years old. Only about a third of the 
patients reported diabetes mellitus (Table 2). At 
the start of observation (before the physicians had 
changed the patients’ medication to the single-
pill triple therapy with A+V+H), the patients were 
taking 4.9 ± 3.1 pills (mean ± standard deviation 
[SD]) per day for the treatment of any indication 
(median: 4.0 pills) and 3.1 ± 2.0 pills (mean ± SD) 
per day of these for treatment of hypertension 
(median: 3.0 pills). Slightly more than a quarter 
of the patients were taking ≥6 pills (Table 3). 
Patient Questionnaire
Patients of either gender suffering from 
essential hypertension for whom treatment 
with A+V+H was indicated according to the 
Table 1  Continued
(b)
Physician questionnaire
No. Questions Potential answers
1) e number of pills that chronically ill patients have to 




Agree Disagree Strongly 
disagree
2) In the daily treatment routine, chronically ill patients 
describe a high number of pills as a burden.
Strongly 
agree
Agree Disagree Strongly 
disagree
3) I am informed about the importance of the 
topic “number of pills and treatment adherence 
(compliance/persistence) and the associated impact.”
Strongly 
agree
Agree Disagree Strongly 
disagree
4) I would like more information about the topic 
“number of tablets and treatment adherence 
(compliance/persistence) and the associated impact.”
Strongly 
agree
Agree Disagree Strongly 
disagree
5) If possible, I prefer combination products because they 
help me to reduce the number of tablets my patients 
have to take every day.
Strongly 
agree
Agree Disagree Strongly 
disagree
6) For my patients, I consider the benet of the triple 
combination of A+V+H in reducing the number of 
tablets to be as follows:
Very high High Fair Low
A+V+H amlodipine, valsartan, and hydrochlorothiazide 
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physician’s opinion were included into this 
noninterventional study. At the start of the 
observational period (i.e., before being treated 
with A+V+H), patients filled in a questionnaire 
concerning the influence of the high number 
of pills (nine items) and physicians filled in a 
questionnaire concerning the impact of the high 
number of pills on the daily practice (six items). 
Burden and Perception of Disease
When asked, the majority of patients stated that 
having to take several pills per day was a burden 
for them (Fig. 1). This percentage increased 
considerably with an increasing number of pills 
per day. Similarly, the number of pills per day 
seemed to have an influence on how sick the 
patients felt. The percentage of patients agreeing 
to the statement “The number of pills I need to 
take influences how sick I feel” was clearly lower 
in patients taking ≤3 pills per day (strongly 
agree: 18.0%; agree: 32.6%) than in patients 
taking >6 pills per day (strongly agree: 37.4%; 
agree: 32.5%). 
Need for Assistance and Expenditure of Time 
Concerning Management of Medication
The majority of patients (overall 85.7% of 
patients) stated that they did not need any help 
to prepare the intake of pills for the day/week at 
home (Table 1, patient questionnaire, item 3). 
The higher the number of pills, the more 
patients needed help, i.e., 22.8% needed help in 
patients with >6 pills a day, whereas only 6.1% 
needed help in patients with ≤3 pills. 
Approximately two thirds of the patients 
(62.6%) stated that the average time needed for 
the preparation of pill intake was 5 min or less. 
The percentage of patients who needed more than
10 min for this task increased with increasing 
number of pills. A clear increase was seen 
between ≤3 pills and >3 pills: for ≤3 pills only 
4.4% of patients needed more than 10 min, 
Table 2  Baseline demographics and characteristics  
(n = 7,101)















Patients with specication 




Table 3  Total number of pills per day before start of 
therapy 
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while for >3 pills, 10% of patients needed more 
than 10 min. 
As expected, the percentage of patients who 
needed more than 10 min also increased with 
increasing age, reaching a value of 20.8% in 
>79 year olds. 
Impact of Pill Color and Shape/Change of 
Compound
The color and shape of the pills appeared to play 
an important role as guidance for the intake of 
pills (Table 1, patient questionnaire, item 5a) in 
the majority of patients (74.3%). In this context, 
the importance of color and shape increased 
with the number of pills that patients had to 
take. A total of 82.2% of the patients who were 
taking >6 pills considered color and shape an 
important landmark, in contrast to 67.6% of 
patients who were taking ≤3 pills. 
Concerning age, the importance attributed 
to color and shape is higher in older (83.8% in 
≥80 year olds) than in younger patients (64.9% 
in <50 year olds).
Another issue in the context of color and 
shape was the question of whether the correct 
use of the medication is harder for the patients 
when the medication’s appearance changes 
(e.g., caused by a change in compound or 
triggered by changes in rebate contracts 
of health insurances with pharmaceutical 
companies; Table 1, patient questionnaire, item 
5b). The majority of patients (79.4%) claimed 
that this was the case. As even the younger 
patients (<50 years) stated this in the majority 
of cases (66.3%), it is not surprising that 89.6% 
of the oldest subgroup (≥80 year olds) agreed 
that the correct use of the medication is harder 
when the appearance changes.
Consequently, there is also a clear correlation 
between the current pill burden and the 
problems that patients expect when they 
change to another compound with a different 
appearance, as shown in Fig. 2. 
Approximately half of the patients stated 
that they were concerned about accidentally 
forgetting pills, or taking the wrong pills or the 
wrong dose of their pills. An increasing number 
of pills (i.e., increasing pill burden) aggravates 
the situation (Table 1, patient questionnaire, 
item 6; Fig. 3). 
Fig. 1  Patient questionnaire: answers to item 1, “Having to take several pills per day is a burden for me.” Note: the 
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Similarly, concern about medication errors is 
of higher relevance in older patients (≥80 year 
olds: 66.9%) than in younger patients (<50 year 
olds: 36.2%).
In fact, 59.3% of the patients admitted 
that they had already been uncertain at times 
whether they had already taken their pills or 
not. When asked how often this had happened, 
56.9% answered that this had happened at least 
occasionally. Higher numbers of pills per day 
also lead to higher percentages of patients who 
claimed that they had often or occasionally been 
uncertain whether they had already taken their 
pills or not (≤3 pills per day: 6.1% often and 
41.7% occasionally; >6 pills per day: 16.5% often 
and 48.6% occasionally). 
Fig. 2  Patient questionnaire: answers to item 5b, “If yes to the previous question (Are pill color and shape a signicant help 
for orientation during drug intake?): the correct use of drugs is harder for me when their appearance changes, e.g., caused by 
a change in compound.” Note: the percentages do not always add up to 100% as the answer to this item on the questionnaire 
























Fig. 3  Patient questionnaire: answers to item 6, “I am worried that I erroneously forget pills or take the wrong pills/the 
wrong dose.” Note: the percentages do not always add up to 100% as the answer to this item on the questionnaire was 
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When asked “What maximal number of 
pills per day would you consider your personal 
acceptable limit when it is possible to have the 
same standard of care?” 10.9% defined 1 pill, 
18.0% defined 2 pills, and 18.3% defined 3 pills 
as the limit. About a quarter of patients (24.5%) 
stated that there was no limit.
Willingness to Make an Additional Out-of-
Pocket Payment
The fact that a high number of pills to be 
taken daily constitutes a massive burden for 
the patients is further highlighted by the fact 
that more than half of the patients (50.6%) 
would be willing to make additional out-of-
pocket payments if this would result in having 
to take only half as many pills with the same 
standard of medical care. This statement was 
mostly independent of the actual pill burden 
and the age of the patients. In patients taking 
≤3 pills, 46.1% would be willing to make 
additional payments, and in patients taking 
>6 pills, 54.2% would be willing to make 
additional payments.
When asked about the amount of money 
that they would be willing to pay additionally, 
most patients would be willing to pay up to 
10 Euro (€) per month (see Fig. 4). 
Subgroups
The results of the patient questionnaire were 
further evaluated with regard to specific 
subgroups by age, gender, and the presence of 
additional diseases, such as diabetes mellitus. 
A number of subgroups showed a consistently 
higher level of agreement with the statements 
made in the questionnaire than other subgroups. 
As already specified before, these were the elderly 
patients (especially those ≥80 years old), patients 
with a high pill burden, and patients suffering 
from diabetes mellitus. 
Physician Questionnaire
A total of 905 physicians’ questionnaires 
were analyzed. The results of the physician 
questionnaire suggest that pill burden in 
chronically ill patients also constitutes a 
challenge for the physicians. When asked, a total 
of 93.6% of physicians strongly agreed or agreed 
to the respective statement. Patients seem to 
actively address the issue and expected guidance 
Fig. 4  Willingness to make an additional out-of-pocket payment for halving the number of pills. Note: the percentages do 







20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
Up to 5€ per month
Up to 10€ per month
Up to 20€ per month
Up to 50€ per month
























Adv Ther (2013)  30(4):406–19. 415
from their physicians. The vast majority of 
physicians (95.8%) strongly agreed or agreed 
that in the daily practice the chronically ill 
patients described the high number of pills as 
a burden. 
Most physicians regarded themselves as 
well informed on the importance of the topic 
“number of pills to be taken and compliance,” 
and its impact (98.1% strongly agreed or agreed), 
and did not wish to receive to receive more 
information on the topic (62.8%). 
In line with these statements, the vast 
majority of physicians (95.7%) also stated that 
– whenever possible – they preferred the used 
of combination products, because these helped 
reduce the number of pills that their patients 
had to take. When asked specifically about 
their assessment of the usefulness of the triple 
combination (A+V+H), the vast majority of 
physicians answered with “high” (38.9%) or 
“very high” (58.9%). 
DISCUSSION
The present study summarized the results of 
a noninterventional study in patients with 
hypertension. The aim of the study was to 
investigate how patients with hypertension and 
their treating physician dealt with the often high 
number of pills, and what kinds of challenges 
they were facing. 
The patient questionnaire in the present 
study showed that patients consider having to 
take several pills per day a burden and that this 
also had an influence on how sick they feel. 
This was also corroborated by the physicians’ 
questionnaire. The vast majority of physicians 
reported that in daily practice the chronically 
ill patients described the high number of pills 
a burden.
This effect is more pronounced in patients 
with a higher number of pills than in those 
with a lower number of pills. Elderly patients 
and patients suffering from diabetes mellitus 
are additional subgroups who seem to be more 
prone to regarding a high number of pills per day 
as a burden. This may be related to the fact that 
these subgroups may also be prone to having a 
higher pill burden than younger patients and 
patients not suffering from diabetes mellitus.
The present study also showed that the 
physicians were aware of the problems that are 
generally associated with the high pill burden 
and the effect it had on compliance. The vast 
majority of physicians stated that they were 
prepared to prescribe combinations in order to 
reduce the pill burden. Nevertheless, this seems to 
have little effect on daily practice as the patients 
were taking an average of 5 pills per day and 
more than a quarter of the patients were taking 
≥6 pills. The reasons for this discrepancy need to 
be elucidated and potential solutions identified. 
One potential solution could be to improve the 
knowledge of physicians on how to best treat 
hypertension, with an important goal being to 
increase patient compliance. Studies have shown 
that physicians who have been specifically 
trained in the guidelines on the treatment of 
hypertension more often achieved target blood 
pressure in their patients than physicians who 
had not received training [17], and that patients 
of trained physicians showed a significantly 
higher compliance than patients of physicians 
who had not been specially trained [18].
In addition to the physician, patient 
compliance is also a key factor when it comes to 
the effectiveness of a therapeutic intervention. 
Features that influence compliance are 
demographic characteristics, side effects of 
the therapy, how simple the intake of the 
medication is, costs of the medication, and 
the number of pills to be taken [19, 20]. The 
importance of the latter has been underlined by 
the results of the present study. Approximately 
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randomized controlled trials. Some researchers 
conclude that – despite all the criteria and 
algorithms available – reducing polypharmacy 
and avoiding inappropriate medications is a 
highly individualized process, which is different 
for each patient, and clinicians will have to use 
extensive clinical judgment [28]. Thus, taken 
together, adequate therapeutic intervention 
in patients with hypertension will need to be 
effective and safe while not adding to the pill 
burden that already seems to be high in this 
patient population, which often also suffers 
from additional comorbidities.
Among the potential weaknesses of the 
present study is the fact that the questionnaire 
used was not a validated questionnaire and, 
thus, cannot be used to compare with results 
from other studies e.g., in other countries. 
Another issue to keep in mind when interpreting 
the study data is the fact that the patients filled 
in the questionnaires at the first visit of an 
observational study that specifically included 
patients whom their physician had decided 
to treat with the triple therapy A+V+H. This 
could lead to a selection bias, with the treating 
physician mainly including the more “severe” 
cases because they are more likely to need a triple 
combination. The questionnaires were applied 
at the start of the study; therefore, it simply 
evaluates the situation of the individual at the 
beginning of the study, and it is not possible to 
assess if and how treatment with A+V+H would 
have impacted the responses.  
A considerable strength of the results 
presented is the large number of patients and 
physicians included. The setting of the study 
allowed the authors to collect data in a real-
life situation, which provides information 
on typical patient characteristics and current 
treatment approaches [29–31]. It also provided a 
sufficiently large sample size to allow for analysis 
of differences between the subgroups, e.g., by 
half of the patients stated that they were 
concerned about accidentally forgetting pills, or 
taking the wrong pills or the wrong dose of their 
pills. This concern increased with increasing pill 
burden and increasing age. If patients take the 
wrong pills, the wrong dose of pills, or too many 
pills, this could result in safety issues, especially 
in light of advanced age and comorbidities. 
Especially when multiple generic versions of a 
drug are available, patients may be exposed to 
a frequent change in the appearance of their 
drugs. Potential pharmacy dispensing errors may 
then not be apparent for the patients anymore 
and patients themselves may mistake one drug 
for another. Also, forgetting pills could reduce 
the effects of their treatment as the medication 
is not administered in the optimal dose range.   
Generally, polypharmacy, defined as the 
use of five or more medications, is a problem 
in patients as it increases the possibility of 
experiencing adverse effects from multiple 
treatments [21–26]. Thus, several approaches 
to reduce polypharmacy have been explored. 
Interventions,  such as  computerized 
decision support or complex, multifaceted 
pharmaceutical care, showed reductions in 
the summated Medication Appropriateness 
Index and in the number of Beers drugs per 
patient, and a significant reduction in the 
number of adverse drug events [26]. However, 
it was unclear if the intervention also resulted 
in a clinically significant improvement [26]. 
Another approach, Good Palliative-Geriatric 
Practice algorithm for drug discontinuation, 
was developed by Garfinkel et al. in a 
prospective interventional study [27]. Successful 
discontinuation of drugs was achieved in 81% 
of patients. Of the discontinued drug therapies, 
2% were restarted because of recurrence of the 
original indication. A total of 88% of patients 
reported global improvement in health. 
However, this tool still needs to be tested in 
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number of total pills daily or by age group. The 
number of patients was similar to the number 
that was used in the retrospective study on 
predictors of adherence with antihypertensive 
(and lipid-lowering) treatment in the US [12]. 
CONCLUSION
In conclusion, a high number of pills is 
considered a burden by patients. This burden 
increases with the number of pills taken per day 
and needs to be actively addressed, especially in 
elderly patients and those with comorbidities. 
Further research is necessary to evaluate which 
approaches may be most promising.
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